NCT02430350

Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled PhaseⅢTrial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,200 (actual)
• Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 35 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner. The study is also to examine the safety of compound Edaravone Injection for the AIS patients.

Conditions

• Acute Ischemic Stroke

Interventions

Type	Name	Description
DRUG	Compound Edaravone Injection
DRUG	Edaravone Injection

Timeline

• Start date: 2015-05-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2015-04-30
• Last updated: 2017-01-16

Locations

48 sites across 1 country: China